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Purpose: The genetic component underlying variation in central corneal thickness (CCT) in the normal population remains
largely unknown. As CCT is an identified risk factor for open-angle glaucoma, understanding the genes involved in CCT
determination could improve our understanding of the mechanisms involved in this association.
Methods: To identify novel CCT genes, we selected eight different candidates based on a range of criteria. These included;
aquaporin 1 (AQ1), aquaporin 5 (AQ5), decorin (DCN), fibrillin-1 (FBN1), keratocan (KERA), lumican (LUM), osteoglycin
(OGN), and paired box 6 (PAX6). Tagging single nucleotide polymorphisms (SNPs) selected from the HapMap database
were genotyped to cover the majority of genetic variation within each gene. Each SNP was screened in a large, population-
based cohort from Australia and both single SNP and haplotype analyses were undertaken.
Results: Two SNPs were found to be nominally associated with CCT, rs17352842 from FBN1 (p=0.02) and rs3026398
from PAX6 (p=0.02), although neither of these p values survived correction for multiple testing. Haplotype analysis
revealed one haplotype within FBN1 (corrected p=0.048) and two haplotypes within PAX6 (strongest corrected p=0.006)
associated with CCT. No other SNPs or haplotypes from the remaining genes showed any significant correlation with
CCT.
Conclusions: Results from this study suggest that FBN1 and PAX6 are potentially involved in determining CCT. This is
the first published study to investigate these genes for association with normal CCT variation.
The identification of central corneal thickness (CCT) as
a risk factor for the potentially blinding condition open-angle
glaucoma (OAG) has stimulated interest in understanding the
genetic mechanisms of this trait. Evidence from numerous
studies  has  identified  lower  CCT  measurements  as  a  risk
factor  for  progression  from  ocular  hypertension  to  OAG
[1-3], greater severity of visual field damage [4,5], and more
rapid  progression  of  established  visual  field  loss  [6-8].
Interestingly, several of these studies also demonstrate that
this relationship is independent of the known confounding
effect CCT has on intra-ocular pressure measurements [1,3,
8], suggesting that the association between CCT and OAG
may be more than just tonometry artifact. If a genuine biologic
interaction exists between structures in the cornea and those
important in OAG pathology, then this raises the possibility
that genes involved in the determination of CCT may also
predispose to OAG.
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Within  the  general  population,  CCT  is  a  normally
distributed quantitative trait, with evidence from twin and
familial studies indicating that it is highly heritable [9-11].
However, despite its high heritability, little is known about the
genes that contribute to normal CCT variation within the
general  population.  Recently,  a  candidate  gene  study
identified  an  association  with  the  type  I  collagen  genes
COL1A1 and COL1A2 and normal CCT variation, but these
have been the only genes identified to-date [12]. These genes
were selected based on the observation that patients with the
connective tissue disorder osteogenesis imperfecta, which is
caused  by  mutations  in  COL1A1  and  COL1A2,  have
abnormally  thin  CCT  measurements  [13,14].  There  are
several other genetic conditions that exhibit abnormal CCT
measurements,  including  Marfan  syndrome  [15,16]  and
aniridia  [17,18],  thus  implicating  the  defective  genes,
fibrillin-1 (FBN1) [19,20] and paired box 6 (PAX6) [21,22],
respectively, as potential modifiers of CCT.
Apart from identifying genes for normal CCT variation
based  on  observations  in  genetic  disorders,  structural  and
metabolic  proteins  within  the  cornea  also  offer  plausible
candidates. The predominant layer of the cornea, the corneal
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562stroma,  is  largely  comprised  of  extracellular  material
including collagens and proteoglycans. A family of proteins
termed  the  small  leucine-rich  proteoglycans  (SLRPs)  are
prominent  within  the  stroma  and  have  a  pivotal  role  in
maintaining the structural integrity of the extracellular matrix,
which is vital for corneal transparency. Some of these SLRPs
include decorin (DCN), keratocan (KERA), lumican (LUM),
and osteoglycin (OGN). Evidence from human and animal
studies also suggests these proteins may play a role in the
determination of CCT. Mutations in DCN result in a disorder
known as congenital corneal stromal dystrophy, which causes
an abnormally thick cornea [23]. Mice with KERA and LUM
gene  knockouts  have  thin  corneal  stromas  [24-26],  while
OGN knockout mice have thicker corneal collagen fibrils
[27]. Another group of proteins that may play a role in CCT
determination are the aquaporins. Mice carrying an aquaporin
1 (AQP1) gene knockout exhibit a decreased CCT, while mice
with an aquaporin 5 (AQP5) knockout show an increased CCT
[28].
In this study, we aimed to evaluate each of these candidate
genes (AQP1, AQP5, DCN, FBN1, KERA, LUM, OGN, and
PAX6) to establish whether any were associated with normal
CCT variation in the general population. We hypothesized
that  common  polymorphisms  within  these  genes  could
contribute to normal variation in CCT, as opposed to the more
deleterious mutations and knockouts seen in the human and
animal models with extreme CCT values. To screen for the
majority of known common genetic variation within these
genes,  we  employed  a  tagging  single  nucleotide
polymorphism (SNP) approach by selecting SNPs from the
HapMap database. The cohort we used for this study was from
a large, population-based study based in the Blue Mountains
region, west of Sydney, Australia.
METHODS
Participant recruitment: Participants were recruited as part of
the Blue Mountains Eye Study (BMES), a population-based
survey  of  vision  and  common  eye  diseases  in  the  Blue
Mountains region, west of Sydney, Australia. The participants
recruited for this study were predominately Caucasian and the
population has been described in detail previously [29]. As
part of the ocular examination, CCT was measured using
ultrasound pachymetry. Genomic DNA was extracted from
peripheral blood according to standard methods. In total, there
were 956 subjects with CCT measurements who were eligible
to be included. The mean CCT of the BMES population was
539.7±32.8 µm and was normally distributed. Average age of
the BMES cohort was 73.8 years, ranging from 60 to 95 years
of age. Sex representation was slightly skewed with 59.9% of
participants  being  female,  while  there  were  62  (6.5%)
confirmed cases of OAG within the cohort. Ethical approval
was obtained from the relevant committees of the Westmead
Millennium Institute at the University of Sydney (Sydney,
Australia), as well as that from Flinders Medical Centre and
Flinders University (Adelaide, Australia). The study adhered
to the tenets of the Declaration of Helsinki.
Genotyping of candidate genes in BMES cohort: For assessing
the association of candidate genes with CCT, tagging SNPs
were  chosen  from  the  Centre  d’Etude  du  Polymorphisme
Humain from Utah (CEU) population of the HapMap project
[30],  using  Haploview  v4.0  software  [31].  Linkage
disequilibrium blocks were defined using the ‘solid spine of
LD’ function. An r2 threshold of 0.8 was set and SNPs with a
minor allele frequency of <0.05 were excluded. The number
of tagging SNPs selected for each gene was as follows, with
the percentage of total genetic variation covered by the SNPs
in parentheses; AQP1-10 (97.5); AQP5-10 (97.6); DCN-10
(98.3);  FBN1-8  (94.1);  KERA-11  (94);  LUM-11  (92.5);
OGN-5 (98.4); and PAX6-7 (96.3).
Genotyping  was  performed  using  iPLEX  GOLD
chemistry (Sequenom Inc., San Diego, CA) on an Autoflex
Mass  Spectrometer  (Sequenom  Inc.)  at  the  Australian
Genome Research Facility, Brisbane, Australia. In the first
phase  of  genotyping,  tagging  SNPs  from  all  genes  were
genotyped in the extreme upper and lower quintiles (above the
80th or below the 20th percentile points) of the normal CCT
distribution, drawn from the 956 subjects in the BMES. In the
extreme  upper  quintile,  all  subjects  had  a  CCT  above
567.26 µm, while all subjects in the extreme lower quintile
had a CCT below 510.75 µm. This methodology was used in
the initial analysis to enrich for genetic effects contributing to
the extremes of CCT variation, thus allowing us to prioritise
SNPs to be screened in the full BMES cohort. Both the upper
and lower quintiles contained 188 subjects each. Alleles and
genotypes were tested for association with thin CCT using the
software  program  PLINK  v1.06  in  a  case-control  design
[32]. The second phase involved screening associated SNPs
from the first phase in the remaining samples from the BMES
cohort and analysis of the entire cohort using the quantitative
trait  CCT  as  the  phenotype.  An  adjusted  p  value  was
calculated  for  each  SNP  using  linear  regression  by
incorporating both sex and age as covariates. Correction of p
values for multiple testing was undertaken using the online
SNPSpD interface [33,34]. The standard Bonferroni method
of  multiple  testing  correction  is  overly  conservative,
particularly when tests are not completely independent, as is
the case here when SNPs are in linkage disequilibrium with
each other. The correction method offered on the SNPSpD
interface accounts for linkage disequilibrium between SNPs
and determines the total number of independent tests per gene.
Haplotypes from both experimental phases were estimated
and  association  tested  using  HaploStats  v1.3.1  software
(Mayo Clinic, Rochester, MN). Haplotypes were primarily
constructed based on LD block structure, although various
combinations  of  sequential  SNPs  were  also  tested  for  all
genes. Correction for multiple testing was performed using a
standard  Bonferroni  adjustment  for  the  total  number  of
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p<0.05.
Power calculations were conducted for the case-control
analysis  using  the  Genetic  Power  Calculator  [35].
Calculations were performed with risk allele frequencies of
0.2, 0.3, and 0.4. Genotype relative risks for the heterozygous
and  homozygous  genotypes  were  set  at  1.5  and  2.25,
respectively. Linkage disequilibrium between the marker and
risk allele was set at D’ prime=1.0. Under these criteria, the
cohort had a power of 78.4% at a risk allele frequency of 0.2,
82.9% at 0.3 and 81.6% at 0.4 when calculated for a dominant
model.
RESULTS
Case-control analysis: The p values for both the dominant and
recessive inheritance models of all the tagging SNPs typed in
the extreme quintiles of the BMES distribution are shown in
Table 1. Of the 71 total SNPs that were genotyped, 12 had a
very  low  minor  allele  frequency  and  did  not  yield  any
association results. There were 6 SNPs in total that had a p
value  below  the  nominal  significance  level  of  0.05;
rs17352842  and  rs9806323  (FBN1);  rs11105956  and
rs12231819 (KERA); rs2761678 (OGN); rs3026398 (PAX6).
However,  only  one  of  these  SNPs,  rs17352842,  survived
correction for multiple testing. Using the modified correction
value calculated by SNPSpD for FBN1, the adjusted p value
for  rs17352842  was  determined  to  be  0.037.  To  decide
whether to screen these six SNPs in the full BMES cohort, we
also assessed whether there were any significant haplotype
associations in the relevant genes. Both FBN1 and PAX6 also
showed significant haplotype associations (data not shown),
while no significant haplotypes involving KERA and OGN
were observed. Thus, all SNPs from FBN1 and PAX6 were
typed in the full cohort.
Quantitative trait analysis: In total, 15 SNPs were genotyped
in the full cohort, comprising eight from FBN1 and seven from
PAX6. Of these 15 SNPs, only two, rs17352842 from FBN1
and  rs3026398  from  PAX6,  showed  any  significant
association  with  CCT  in  the  full  cohort.  The  genotype
frequencies,  mean  CCT  values  for  each  genotype  and
TABLE 1. RESULTS OF ASSOCIATION TESTS FOR SNPS FROM ALL THE CANDIDATE GENES IN THE CASE-CONTROL ANALYSIS.
      p value   p value
Gene SNP MAF Dominant Recessive Gene SNP MAF Dominant Recessive
AQ1 rs7788618 0.16 0.49 0.42 KERA rs10745549 0.1 0.23 0.1
  rs1476597 0.44 0.82 0.6   rs2701166 0.26 0.7 0.08
  rs1004317 0.36 1 0.5   rs1920773 0.08 0.87 0.24
  rs17159702 0.24 0.059 0.085   rs11105956 0.06 0.41 0.041
  rs1049305 0.39 0.85 0.62   rs11105957 0.18 0.23 0.37
  rs13222180 0.24 0.18 0.57   rs17018627 0.06 0.98 0.24
  rs10244884 0.48 0.16 0.89   rs10859103 0.2 0.67 0.67
AQ5 rs3741559 0.2 0.59 0.93   rs10859104 0.09 0.67 0.092
  rs461872 0.47 0.98 0.35   rs12230223 0.17 0.48 0.53
  rs10875989 0.3 0.88 0.42   rs12231819 0.09 0.51 0.041
  rs2878771 0.2 0.43 0.8 LUM rs10745551 0.31 0.55 0.93
  rs3759129 0.22 0.77 0.8   rs10777286 0.43 0.2 0.42
  rs296759 0.36 0.88 0.52   rs10777287 0.11 0.19 0.24
  rs296763 0.23 0.15 0.16   rs10859105 0.25 0.95 0.56
  rs1996315 0.43 0.35 0.8   rs11105987 0.12 0.7 0.1
  rs2849266 0.08 0.19 0.1   rs7976738 0.13 0.29 0.55
  rs10875990 0.06 0.096 0.24   rs11478 0.08 0.53 0.96
DCN rs12819853 0.3 0.67 0.85   rs2268578 0.11 0.74 0.24
  rs17658598 0.15 0.77 0.32 OGN rs7047089 0.33 0.11 0.85
  rs17658685 0.04 0.3 0.23   rs10761156 0.49 0.46 0.071
  rs566806 0.25 0.91 1   rs2761678 0.1 0.091 0.018
  rs741212 0.12 0.76 0.42   rs2761680 0.12 0.4 0.54
  rs10492230 0.16 0.98 0.5 PAX6 rs3026398 0.28 0.011 0.15
FBN1 rs17352842 0.2 0.0056 0.45   rs662702 0.05 0.3 0.24
  rs10519177 0.25 0.95 0.75   rs2071754 0.21 0.18 0.3
  rs9806323 0.14 0.033 0.37   rs3026390 0.49 0.24 0.18
  rs683282 0.32 0.51 0.75   rs7942007 0.2 0.86 0.16
  rs12915677 0.17 0.57 0.36   rs12286701 0.03 0.28 0.24
  rs17364665 0.05 0.2 0.24          
  rs591519 0.09 0.085 0.98          
  rs11854144 0.12 0.11 0.14          
Results of association tests for tagging SNPs from all candidate genes screened in the extreme lower and upper CCT quintiles
derived  from the 956 normal individuals of the entire BMES cohort. Both the lower and upper quintiles contained 188 subjects
each. P values are given for both the dominant and recessive models, with values in bold considered significant at the p<0.05
level. In the table, MAF=minor allele frequency.
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564associated  p  values  for  these  two  SNPs  and  the  other
significant  FBN1  SNP  from  the  first  phase  genotyping
(rs9806323)  are  illustrated  in  Table  2.  As  there  were  no
significant associations among the remaining 13 SNPs, these
are not shown, but the genotyping data from these SNPs was
used  to  test  for  haplotype  associations.  The  FBN1  SNP
rs17352842  was  nominally  associated  with  CCT  under  a
dominant model, with an unadjusted p value of 0.02, with no
change after adjustment for age and sex. This p value did not
survive correction for multiple testing. The findings were
similar  for  the  PAX6  SNP  rs3026398,  with  a  nominally
significant p value of 0.02 under a dominant model in both the
unadjusted and adjusted analysis. Again, this p value did not
survive correction for multiple testing.
Results of the haplotype analysis performed on FBN1 and
PAX6 can be seen in Table 3 and Table 4. The CT haplotype
in  FBN1,  which  comprises  SNPs  rs17352842  and
rs9806323, was significantly associated with CCT under an
additive and recessive model. However, following Bonferroni
correction for the four observed haplotypes, only the value
under the recessive model remained significant at p=0.048. A
two  SNP  haplotype  in  PAX6  comprising  rs3026398  and
rs662702 was found to be significantly associated with CCT
under all three inheritance models. The strongest association
was seen with the GC haplotype under a recessive model,
which gave a p value of 0.009 following correction for the
three observed haplotypes. Both the GC haplotype under an
additive model and the AC haplotype under a dominant also
yielded  p  values  that  survived  Bonferroni  correction  for
multiple testing.
DISCUSSION
The genetic factors involved in the determination of CCT are
largely unknown. This is despite several familial and twin
studies indicating that CCT exhibits a very strong hereditary
component [9-11]. These characteristics make CCT ideal for
a candidate gene study, particularly given that as with any
quantitative trait, CCT is likely to be under the regulation of
numerous genes. For this study, we selected eight different
candidate genes that we hypothesized to be associated with
CCT. The selected genes can be divided into three broad
groups based on their similarities; the aquaporins - AQP1 and
AQP5; SLRPs of the cornea - DCN, KERA, LUM, OGN; and
genes  associated  with  abnormal  CCT  in  disease  states  -
FBN1 and PAX6. Our hypothesis was that non-pathogenic
polymorphisms within these genes could be associated with
TABLE 2. ASSOCIATION OF FBN1 AND PAX6 SNPS WITH CCT IN THE FULL COHORT.
    Unadjusted p value Adjusted p value
Gene SNP Genotype Frequency Mean CCT
±SD (µm)
Dominant Recessive Dominant Recessive
FBN1 rs17352842 C/C 0.63 541.3±32.4 0.02 0.81 0.02 0.94
    C/T 0.32 535.9±32.4        
    T/T 0.05 538.2±32        
  rs9806323 T/T 0.70 541.6±33.2 0.09 0.68 0.11 0.59
    T/A 0.27 536.8±31.8        
    A/A 0.03 543±29.3        
PAX6 rs3026398 G/G 0.50 536.7±33.3 0.02 0.8 0.02 0.72
    G/A 0.42 542.1±31.9        
    A/A 0.08 540.2±30.7        
Genotype frequencies and mean CCT values for each genotype of selected SNPs from FBN1 and PAX6 typed in 956 subjects
from the full BMES cohort. P values are calculated for both dominant and recessive modes of inheritance with the adjusted p
value corrected for sex and age. Values in bold are considered significant at the p<0.05 level. In the table, SD=standard deviation.
TABLE 3. ASSOCIATION OF HAPLOTYPES IN FBN1 WITH CCT IN THE FULL COHORT.
 
SNP   p value
Haplotype 1 2 Frequency Additive Dominant Recessive
1 T A 0.10 0.138 0.073 0.534
2 T T 0.11 0.147 0.133 0.810
3 C A 0.06 0.548 0.580 NA
4 C T 0.73 0.027 0.589 0.012
A two SNP haplotype was constructed from FBN1   SNPs using rs17352842 (SNP 1) and rs9806323 (SNP 2). This haplotype
was assessed in 956 subjects from the full BMES cohort and tested for association with CCT as a continuous variable. Additive,
dominant and recessive modes of inheritance were analyzed and values in bold survived Bonferroni correction for the four
observed haplotypes. Values were considered significant at the p<0.05 level following correction.
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565the normal CCT variation seen within the general population
and our approach to find these variants was to select a range
of tagging SNPs that would cover the majority of genetic
variation within these genes.
Both  AQP1  and  AQP5  are  water  channel  proteins
expressed in the mammalian cornea, including human cornea
[36-38]. AQP1 is expressed in the corneal endothelium while
AQP5  is  found  in  the  epithelium  and  they  both  play  an
important role in the regulation of fluid transport, which is
essential  for  maintaining  corneal  transparency.  To  further
characterize the function of these aquaporins, Thiagarajah et
al. [28] studied the corneas of mice with Aqp1 and Aqp5 gene
knockouts. They observed that the  Aqp1 null mice had a
significantly reduced corneal thickness, while the Aqp5 mice
had  a  significantly  increased  corneal  thickness.  The
mechanism  responsible  for  this  change  is  likely  to  be
alterations in the water balance of the corneal stroma, with
dehydration  causing  thinning  of  the  cornea  and  swelling
resulting in a thickening of the cornea. These observations
were the basis for our inclusion of AQP1 and AQP5 in our
candidate  gene  study,  as  we  hypothesized  that  minor
alterations  in  the  water  balance  of  the  cornea  caused  by
polymorphisms in AQP1 and AQP5 may account for some of
the  normal  variation  in  CCT  in  humans.  However,  our
genotyping results indicated that there was no association with
these genes and CCT variation.
This study also examined several genes that code for
SLRPs, a class of proteins that are vital to the development of
a functional cornea. SLRPs are macromolecules composed of
a protein core with covalently linked glycosaminoglycan side
chains, and constitute a major component of the extracellular
matrix, where they form complexes with other matrix proteins
such as collagen [39]. The corneal stroma, which accounts for
approximately 90% of the total thickness of the cornea, is
predominately an extracellular tissue, comprised of a highly
ordered and uniform array of collagen fibrils, features which
are essential for establishing corneal transparency. Corneal
SLRPs play a crucial role in assembling this array. More
specifically, DCN,KERA,LUM, and OGN are all involved in
regulating the diameter and growth of these collagen fibrils,
as well as establishing uniform inter-fibrillar spacing [40].
Alterations in the diameter of collagen fibrils could be of
importance in a human model, where a narrower collagen
fibril diameter has been shown to directly correlate with a
reduction in CCT [41,42]. As discussed previously, there is
also evidence from both human and mouse studies indicating
that mutations or knockouts of these SLRP genes directly
influence CCT [23-26]. This data provided the foundation of
our  hypothesis  that  the  aforementioned  SLRPs  could  be
associated with normal CCT variation. The results of our
genotype screening however, suggests that these genes are not
involved  in  CCT  determination,  with  no  SNPs  surviving
multiple testing correction and no significantly associated
haplotypes.
Two genes were also selected as candidates in our study
based on their causal involvement with diseases that present
with abnormal CCT measurements. FBN1 is an extracellular
glycoprotein that is a constituent of the 8–10 nm microfibrils
that provide structural support to basement membranes and
elastic and non-elastic tissues [43]. Expression of FBN1 is
widespread throughout the body and has been documented in
the cornea [44,45]. Mutations in FBN1 can cause Marfan
syndrome, a connective tissue disorder that results in a range
of clinical manifestations, with the principal complications
occurring  in  the  eye  and  the  skeletal  and  cardiovascular
systems [19,20]. Studies have shown that Marfan syndrome
patients also have a lower CCT [15,16]. The other candidate
gene that was selected based on its association with abnormal
CCT  measurements  in  disease  was  PAX6,  a  transcription
factor that plays an integral role in the early development of
the ocular, central nervous and endocrine systems [46,47].
Mutations in PAX6 have been shown to result in aniridia, a
congenital ocular condition which presents with abnormalities
including  iris  hypoplasia,  corneal  opacities,  cataracts,  and
foveal and optic nerve hypoplasia [21,22]. Aniridia has also
been associated with a significantly thicker CCT [17,18]. It
has been postulated that mutations in PAX6 may disrupt the
normal homeostasis of corneal stromal keratocytes, leading to
increased  stromal  extracellular  matrix  synthesis  and
subsequent  increases  in  CCT  [18].  While  pathogenic
TABLE 4. ASSOCIATION OF HAPLOTYPES IN PAX6 WITH CCT IN THE FULL COHORT.
 
SNP   p value
Haplotype 1 2 Frequency Additive Dominant Recessive
1 G C 0.63 0.008 0.369 0.003
2 G T 0.06 0.301 0.326 0.678
3 A C 0.31 0.025 0.009 0.579
A two SNP haplotype was constructed from PAX6 SNPs using rs3026398 (SNP 1) and rs662702 (SNP 2). This haplotype was
assessed  in 956 subjects from the full BMES cohort and tested for association with CCT as a continuous variable. Additive,
dominant and recessive modes of inheritance were analyzed and values in bold survived Bonferroni correction for the three
observed haplotypes. Values were considered significant at the p<0.05 level following correction.
Molecular Vision 2010; 16:562-569 <http://www.molvis.org/molvis/v16/a64> © 2010 Molecular Vision
566mutations within FBN1 and PAX6 can be directly correlated
with alterations in CCT, these variants would not contribute
to normal CCT variation. Therefore, we hypothesized that
non-pathogenic polymorphisms in either of these genes could
be involved in the more subtle variation in CCT seen in the
general population.
Results from the first phase of genotyping indicated that
SNPs from both FBN1 and PAX6 were suitable for screening
in  the  full  BMES  cohort.  While  only  rs17352842  from
FBN1 survived correction for multiple testing, there were
some  significant  haplotype  associations  that  ensured  both
genes  warranted  further  investigation.  Analysis  of  all  the
FBN1 and PAX6 SNPs in the full BMES cohort however, did
not strengthen the argument that these genes are associated
with CCT variation. The p values from all the significant SNPs
in the first phase genotyping, rs17352842 and rs9806323 from
FBN1 and rs3026398 from PAX6, weakened when assessed
in  the  larger  cohort.  The  reduction  in  significance  is  an
interesting  observation  and  could  be  the  result  of  several
factors.  The  increased  power  provided  by  genotyping  the
SNPs in an additional 580 samples suggests that the initial
analysis was under-powered and that the associations seen
were possibly type I error. Alternatively, the first phase of
genotyping  in  the  upper  and  lower  quintiles  could  have
enriched for variants that are only important in the extreme
ends  of  the  CCT  spectrum  and  thus,  by  introducing  the
samples from the ‘middle’ of the distribution, potentially real
associations could be weakened. This is a potential weakness
of the approach we undertook to prioritize SNPs from the first
phase screen, as we may have ignored SNPs that could have
been significantly associated had they been screened in the
full BMES cohort. However, the reduced cost of genotyping
the extremes in the first instance enabled us to screen more
candidate genes.
The  haplotype  analysis  conducted  on  the  full  cohort
provided additional evidence for an association of these genes
with  CCT,  with  haplotypes  from  both  FBN1  and  PAX6
yielding  significant  p  values  that  survived  Bonferroni
correction. The results suggest there may be variants within
these regions of FBN1 and PAX6 that are involved in CCT
determination, particularly given that the haplotypes for both
genes  contained  the  most  significantly  associated  SNPs.
Given the relatively strong haplotype data, it is intriguing that
single  SNP  analysis  showed  a  weak  or  no  association.
However,  studies  have  demonstrated  that  examining
haplotypes  can  be  superior  to  single  SNP  analysis  when
undertaking a candidate gene study and it is possible that the
haplotypes are detecting variation within these genes that
cannot be ascertained from investigating single SNPs [48,
49]. This scenario also presents an inherent difficulty with the
haplotype  and  tagging  SNP  methodologies,  whereby  the
actual causative variants remain unknown. The contradicting
data presented by the single SNP and haplotype analyses of
FBN1 and PAX6 ensures that further work is needed to assess
the  potential  involvement  of  these  genes  with  CCT
determination. Replication of these results in other cohorts is
required to confirm the findings of this study.
The identification of CCT as a major risk factor for OAG
gives major clinical relevance to understanding the genetic
mechanisms of this trait. OAG is an adult-onset, irreversible
cause of vision loss that will affect an estimated 58 million
people worldwide by 2020, making it the second leading cause
of  blindness  after  cataract  [50].  Due  to  its  increasing
prevalence with age, the burden of OAG on society is likely
to increase substantially as our population ages. In Australia
alone, the estimated annual cost to the economy from OAG
will  be  $4.3  billion  by  2025  [51].  Therefore,  improving
current methods of diagnosis and treatment for this condition
remains  a  priority.  Vital  to  achieving  this  aim  is  the
enhancement  of  our  understanding  of  the  genes  that
predispose to OAG. Despite evidence from familial and ethnic
studies  demonstrating  the  strong  genetic  component
underlying OAG, this facet of the disease remains poorly
characterized [52]. Only one major gene, myocilin (MYOC),
has been identified to-date and mutations in this gene only
account for approximately 3% of cases [53]. With substantial
evidence supporting low CCT as a risk factor for OAG, it is
conceivable that genes may be common to both pathways. A
biological link may exist between aspects of the cornea that
regulate  its  thickness  and  the  physical  and  structural
properties of tissues involved in glaucoma pathogenesis, such
as the lamina cribrosa or trabecular meshwork. Even if no such
biological interaction exists and low CCT is a risk factor
purely due to tonometry artifact, developing our knowledge
of the genetic mechanisms involved in CCT variation will
improve our understanding of the nature of the association
between CCT and OAG.
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